Bioventus Inc. (Class A) (BVS) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, BVS scores 65 out of 100, earning a C grade and the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine (12 / 20): Return on invested capital is 10.4% and FCF yield is 5.77%. These figures show moderate capital efficiency and cash generation relative to the stock price, but not a standout profile.
• Whale 13F Flow (15 / 20): Institutional accumulation and options positioning contribute the strongest pillar score, indicating a relatively constructive institutional footprint, though the underlying holder detail is not provided in source data.
• Insider Conviction (12 / 20): SEC Form 4 and Congressional PTR cluster flow earns a middling score, suggesting insider activity is neither a clear tailwind nor a clear warning.
• Macro Regime Fit (12 / 20): Beta of 1.0 and sector sensitivity place the stock in line with the broader market, offering no defensive cushion or special macro leverage.
• Forensic Balance Sheet (14 / 20): Altman Z of 2.25, Piotroski F of 7/9, and Debt/Equity of 1.52 indicate a leveraged balance sheet with reasonable operating health.

For a prospective investor evaluating the stock today, the upside case rests on cash generation and institutional interest, while the valuation case is constrained by a P/E (TTM) of 55 and EV/EBITDA of 26.3, which price in substantial future growth. Leverage is an ongoing risk factor. The overall rating reflects a balanced risk-reward rather than a clear directional signal.

Bioventus Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, the company is classified under this sector and industry. Not available in source data for product lines, customer segments, or revenue model detail.

Per the SEC financials, operating income moved from negative in FY 2023 and FY 2024 to positive at $54.0M in FY 2025, with net income turning positive at $22.7M. Per the market data, gross margin is 68.3%, operating margin 9.5%, and net margin 4%, with ROIC at 10.4%. Per the Roarable RQD rating, the Altman Z-Score is 2.25 and the Piotroski F-Score is 7/9, and debt/equity is 1.52. Debt declined from $308.3M to $279.0M between FY 2024 and FY 2025.

Per the recent news feed, six items reference BVS: a TradingView estimates report (YELLOW, market wire), a GuruFocus report noting a stock gain of 3.6% alongside a GF Score of 63/100 and an overvalued GF Value assessment (YELLOW, market wire), a Globe and Mail report grouping BVS with Regeneron as bullish healthcare names (GREEN, catalyst), a MarketBeat report referencing an average target price of $16.80 (YELLOW, market wire), a Simply Wall St report on an 85% climb (YELLOW, market wire), and a Stock Traders Daily report on price-sensitive allocations (YELLOW, market wire). The only item tagged as a catalyst is the Globe and Mail piece. Most items are market commentary rather than company-specific events. Per the Butterfly Supply-Chain Graph, no supply chain links or proprietary signals are recorded.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream suppliers, downstream customers, or sector correlation pathways. Investors should note that the absence of mapped links means second-order ripple effects cannot be assessed from the provided data.

• What drives the FY 2025 swing to positive operating and net income, and is it repeatable?
• What is the composition and timing of the debt reduction and maturity profile behind the $279.0M balance?
• Which specific institutional holders and insiders underpin the Whale 13F Flow and Insider Conviction pillar scores?
• What are the company's principal product lines and customer concentration, which the profile does not describe?
• What explains the stock's sharp 52-week range, from $6.47 to $15.89?